Attention pharma: where do diagnostics fit in your future strategy?
Posted 7th March 2012 in Articles, General, R&D | Register to comment
Loïc Kubitza of PwC addresses the importance of diagnostics.
With IVDs becoming more important for drug development, pharmaceutical companies can’t ignore the role of diagnostics…
Read the full articleThe EU generics market: a Greek perspective
Posted 10th January 2012 in Articles, General, Interviews, R&D | Register to comment
Rebecca Aris speaks with the head of the R&D department for generic product development at Genepharm for his insights into the current trends in the EU generics market.
Ahead of his speaking engagement at the Generics & Biosimilars summit 2012, Deepak shares his insights…
Read the full articlePharma emerging markets: what is Latin America’s place within R&D?
Posted 11th May 2011 in Articles, General, R&D | Register to comment
As Latin American markets grow the region offers more attractive opportunities in the research and development field. Here Ruben Gennero and Valentina Jaramillo discuss the pros and cons of R&D in this area.
In a previous post we examined the opportunities offered by Latin-American markets in the pharmaceutical field. The huge…
Read the full articleTrends in pharmaceutical R&D outsourcing
Posted 3rd September 2010 in Articles, General, R&D | Register to comment
As pressure to cut costs in the pharma industry continues, Adwait Bhagwat discusses the increasing trend to outsource R&D.
R&D outsourcing involves pharmaceutical companies subcontracting parts of their R&D efforts to third-party service providers…
Read the full articleThe role of social media in clinical trial recruitment
Posted 7th July 2010 in Articles, R&D | 7 comments
As social media permeates all aspects of healthcare, Sean Johnson explores what role it can play in supporting clinical trial recruitment.
The biggest barrier for pharmaceutical companies to overcome in conducting a clinical trial is actually recruiting patients to participate. This recruiting conundrum has…
Read the full articleThe growth of drug development in emerging markets
Posted 28th June 2010 in Articles, Interviews, R&D | Register to comment
Continuing our interview series, Nathaniel Ramuthaga discusses with pharmaphorum how the clinical research environment is developing in the emerging markets.
It seems that an ever increasing volume of clinical study work is being conducted outside the mature global pharma markets…
Read the full articleWhat Are IDEAs Made Of: Phase III
Posted 19th March 2010 in Articles, R&D | 1 comment
Well, you asked for more R&D articles, so this week Mike Rea turns his thoughts to phase III trials and what might be going wrong.
Patient: “I’ve just gone into phase III! What are my chances of coming through alive?” Doctor: “Well the prognosis is not good – about 20%”
Read the full articleMinimising risks: drug discovery practices for Chief Scientific Officers
Posted 2nd February 2010 in Articles, R&D | 3 comments
pharmaphorum invites feedback from our readers on the recent interview marcus evans conducted with Malcolm Weir, CEO of Heptares Therapeutics, discussing the challenges of drug discovery today.
Statistics seem almost stacked against developing a fitting drug for a target disease. Drug discovery is plagued by time consuming and costly…
Read the full articleDifficult issues in pharma going global (part II)
Posted 14th January 2010 in Articles, R&D | 1 comment
In the concluding part of this two part article, Faiz Kermani explores regulations to control trials in emerging markets and asks whether pharma is being ethical enough in these regions.
In the first part of this article I looked at the growth of clinical development activity in the emerging pharma markets…
Read the full articleDifficult issues in pharma going global (part I)
Posted 12th January 2010 in Articles, R&D | 2 comments
In the first piece of a two part article, Faiz Kermani looks at the emergence of clinical trial activity in emerging markets and explores some of the ethical issues.
Although the economic downturn has had a negative impact, the global pharmaceutical market is still experiencing strong growth…
Read the full article